GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展

被引：5
|
作者：
林楚曼 [1 ]
林伟浩 [1 ]
周蕊 [2 ]
杨力 [3 ]
机构：
[1] 广州, 南方医科大学第二临床医学院
[2] 基础医学院病理学系
[3] 广州,
来源：
国际内分泌代谢杂志 | 2018年 / 38卷 / 03期
基金：
广东省自然科学基金;
关键词：
胰高血糖素样肽-1; 非酒精性脂肪性肝病; 信号通路;
D O I：
暂无
中图分类号：
R575.5 [肝代谢障碍];
学科分类号：
摘要：
既往研究表明, 胰高血糖素样肽-1(GLP-1)可改善肝脏脂肪变性, 特别是在2型糖尿病患者中。研究GLP-1是否作用于肝细胞并影响非酒精性脂肪性肝病(NAFLD)的进展已成为防治NAFLD的研究热点。近年的研究发现, 人肝细胞上有GLP-1受体(GLP-1R)的表达, 提示GLP-1可直接作用于GLP-1R, 并通过cAMP-蛋白激酶A-AMP活化蛋白激酶/沉默信息调节因子1、胰岛素受体底物1-磷酸肌醇依赖性酶1-蛋白激酶C/蛋白激酶B、Janus激酶-信号转导与转录激活因子、内质网转膜蛋白激酶1α-c-Jun氨基末端激酶等信号通路调节脂代谢相关基因的表达, 改善肝脏脂肪代谢。
引用
收藏
页码：179 / 182
页数：4
相关论文
共 24 条
  • [1] GLP-1对非酒精性脂肪肝病大鼠的作用及对PKCε、TLR4/NF-κB信号通路的影响.[D].周小俐.南方医科大学.2015, 03
  • [2] The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis
    Zhou, M.
    Mok, M. T. S.
    Sun, H.
    Chan, A. W.
    Huang, Y.
    Cheng, A. S. L.
    Xu, G.
    [J]. ONCOGENE, 2017, 36 (29) : 4135 - 4149
  • [3] Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators
    Decara, Juan
    Arrabal, Sergio
    Beiroa, Daniel
    Rivera, Patricia
    Vargas, Antonio
    Serrano, Antonia
    Javier Pavon, Francisco
    Ballesteros, Joan
    Dieguez, Carlos
    Nogueiras, Ruben
    Rodriguez de Fonseca, Fernando
    Suarez, Juan
    [J]. BIOFACTORS, 2016, 42 (06) : 600 - 611
  • [4] Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway
    Tong, Wenxin
    Ju, Liping
    Qiu, Miaoyan
    Xie, Qihai
    Chen, Ying
    Shen, Weili
    Sun, Weihong
    Wang, Weiqing
    Tian, Jingyan
    [J]. HEPATOLOGY RESEARCH, 2016, 46 (09) : 933 - 943
  • [5] GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
    He, Qin
    Sha, Sha
    Sun, Lei
    Zhang, Jing
    Dong, Ming
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 476 (04) : 196 - 203
  • [6] Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway
    Wang, Yan-Gui
    Yang, Tian-Lun
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (05) : 1777 - 1783
  • [7] SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
    Xu, Fen
    Li, Zhuo
    Zheng, Xiaobin
    Liu, Hongxia
    Liang, Hua
    Xu, Haixia
    Chen, Zonglan
    Zeng, Kejing
    Weng, Jianping
    [J]. DIABETES, 2014, 63 (11) : 3637 - 3646
  • [8] Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
    Fruci, Barbara
    Giuliano, Stefania
    Mazza, Angela
    Malaguarnera, Roberta
    Belfiore, Antonino
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (11): : 22933 - 22966
  • [9] Hepatic SIRT1 Attenuates Hepatic Steatosis and Controls Energy Balance in Mice by Inducing Fibroblast Growth Factor 21
    Li, Yu
    Wong, Kimberly
    Giles, Amber
    Jiang, Jianwei
    Lee, Jong Woo
    Adams, Andrew C.
    Kharitonenkov, Alexei
    Yang, Qin
    Gao, Bin
    Guarente, Leonard
    Zang, Mengwei
    [J]. GASTROENTEROLOGY, 2014, 146 (02) : 539 - +
  • [10] Prevalence and Control of Diabetes in Chinese Adults
    Xu, Yu
    Wang, Limin
    He, Jiang
    Bi, Yufang
    Li, Mian
    Wang, Tiange
    Wang, Linhong
    Jiang, Yong
    Dai, Meng
    Lu, Jieli
    Xu, Min
    Li, Yichong
    Hu, Nan
    Li, Jianhong
    Mi, Shengquan
    Chen, Chung-Shiuan
    Li, Guangwei
    Mu, Yiming
    Zhao, Jiajun
    Kong, Lingzhi
    Chen, Jialun
    Lai, Shenghan
    Wang, Weiqing
    Zhao, Wenhua
    Ning, Guang
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (09): : 948 - 958
123